Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Weiland, T; Eckert, A; Tomazic, PV; Wolf, A; Pondorfer, P; Vasicek, S; Graupp, M; Holzmeister, C; Moser, U; Andrianakis, A; Kangler, G; Kiss, P; Brcic, L; Kappler, M; Wickenhauser, C; Haak, A; Krüger, M; Al-Nawas, B; Blatt, S; Brockmeyer, N; Skaletz-Rorowski, A; Potthoff, A; French, LE; Charnowski, S; Reinholz, M; Kaufmann, AM; Thies, S; Lambrecht, HG; Seliger, B; Wild, DC; Thurnher, D.
DRH1 - a novel blood-based HPV tumour marker.
EBioMedicine. 2020; 56: 102804-102804. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Andrianakis Alexandros
Brcic Luka
Graupp Matthias
Holzmeister Clemens
Kangler Georg Josef
Kiss Peter
Moser Ulrich Christian
Pondorfer-Schäfer Prisca
Thurnher Dietmar
Tomazic Peter Valentin
Vasicek Sarah Marvis
Weiland Thomas
Wolf Axel
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 7
| | | | | | |
Abstract:
To date, no studies have successfully shown that a highly specific, blood-based tumour marker to detect clinically relevant HPV-induced disease could be used for screening, monitoring therapy response or early detection of recurrence. This study aims to assess the clinical performance of a newly developed HPV16-L1 DRH1 epitope-specific serological assay. In a multi-centre study sera of 1486 patients (301 Head and Neck Squamous Cell Carcinoma (HNSCC) patients, 12 HIV+ anal cancer patients, 80 HIV-positive patients, 29 Gardasil-9-vaccinees, 1064 healthy controls) were tested for human HPV16-L1 DRH1 antibodies. Analytical specificity was determined using WHO reference-sera for HPV16/18 and 29 pre- and post-immune sera of Gardasil-9-vaccinees. Tumour-tissue was immunochemically stained for HPV-L1-capsidprotein-expression. The DRH1-competitive-serological-assay showed a sensitivity of 95% (95% CI, 77.2-99.9%) for HPV16-driven HNSCC, and 90% (95% CI, 55.5-99.7%) for HPV16-induced anal cancer in HIV-positives. Overall diagnostic specificity was 99.46% for men and 99.29% for women ≥ 30 years. After vaccination, antibody level increased from average 364 ng/ml to 37,500 ng/ml. During post-therapy-monitoring, HNSCC patients showing an antibody decrease in the range of 30-100% lived disease free over a period of up to 26 months. The increase of antibodies from 2750 to 12,000 ng/ml mirrored recurrent disease. We can also show that the L1-capsidprotein is expressed in HPV16-DNA positive tumour-tissue. HPV16-L1 DRH1 epitope-specific antibodies are linked to HPV16-induced malignant disease. As post-treatment biomarker, the assay allows independent post-therapy monitoring as well as early diagnosis of tumour recurrence. An AUC of 0.96 indicates high sensitivity and specificity for early detection of HPV16-induced disease. The manufacturer provided assays free of charge. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Find related publications in this database (Keywords)
HPV16
Antibodies
Tumour marker
Screening
Blood test
HNSCC
© Med Uni Graz Impressum